In vitro 5-LOX inhibitory and antioxidant potential of isoxazole derivatives.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2024
Historique:
received: 04 01 2024
accepted: 11 06 2024
medline: 4 10 2024
pubmed: 4 10 2024
entrez: 4 10 2024
Statut: epublish

Résumé

5-Lipoxygenase (5-LOX) is a key enzyme involved in the biosynthesis of pro-inflammatory leukotrienes, leading to asthma. Developing potent 5-LOX inhibitors are highly attractive. In this research the previously synthesized isoxazole derivatives has been investigated against 5-LOX inhibitory and antioxidant in vitro assay. The compound 3 caused concentration dependent inhibition of 5-LOX with overall IC50 value of 8.47 μM. The investigated compounds C5 also exhibited good 5-LOX inhibitory effect. The IC50 demonstrated for C5 was 10.48. Among the 10 synthesized compounds, the potential 5-LOX inhibitory effect was reported for C6. The most potent compound which showed excellent free radical scavenging effect was C3 having IC50 value of 10.96 μM. The next most potent antioxidant activity was reported for C5 which non-significantly showed free radical scavenging effect. The IC50 value observed for C5 was 13.12 μM. Compound C6 also showed potent dose dependent antioxidant effect with IC50 value of 18.87 μM having percent inhibition of 91.63±0.55, 88.45±0.49, 83.53±0.45, 78.42±0.66 and 73.72±0.64 at concentration 1000-62.5 μg/mL respectively. Among the tested compounds, C6 was found most potent which showed significant 5-LOX percent inhibition assay and also reported the minimum IC50 value comparable to the reference drug. The in vitro 5-LOX enzymes inhibition assays of C5 and C3 also showed excellent percent inhibition and good potency next to C6. We concluded that amongst the investigated designed molecules the C3 was found best potent and showed significant dose dependent antioxidant activity against DPPH screening. The IC50 value reported for C3 was found good as compared to standard drug. Moreover, C5 and C6 also showed excellent free radical scavenging effect against DPPH assay. Computational methods have also been employed to explore the probable interaction model of inhibitors and enzyme active sites, and also to correlate the results of in silico and in vitro studies.

Identifiants

pubmed: 39365759
doi: 10.1371/journal.pone.0297398
pii: PONE-D-24-00443
doi:

Substances chimiques

Lipoxygenase Inhibitors 0
Antioxidants 0
Arachidonate 5-Lipoxygenase EC 1.13.11.34
Isoxazoles 0
Free Radical Scavengers 0
Picrates 0
1,1-diphenyl-2-picrylhydrazyl DFD3H4VGDH
Biphenyl Compounds 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0297398

Informations de copyright

Copyright: © 2024 Alam et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Déclaration de conflit d'intérêts

I have read the journal’s policy, and the authors of this manuscript have the following competing interests: Institution.

Auteurs

Waqas Alam (W)

Department of Pharmacy, Abdul Wali Khan University Mardan, Mardan, Pakistan.

Haroon Khan (H)

Department of Pharmacy, Abdul Wali Khan University Mardan, Mardan, Pakistan.

Muhammad Saeed Jan (MS)

Department of Pharmacy, Bacha Khan University, KP, Charsadda, Pakistan.

Hany W Darwish (H)

Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, Riyadh, Kingdom of Saudi Arabia.

Maria Daglia (M)

Department of Pharmacy, University of Napoli Federico II, Naples, Italy.
International Research Center for Food Nutrition and Safety, Jiangsu University, Zhenjiang, China.

Ahmed A Elhenawy (A)

Chemistry Department, Faculty of Science, Al-Azhar University, Nasr City, Cairo, Egypt.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH